Iwase, Madoka http://orcid.org/0000-0002-4423-4023
Ando, Masashi http://orcid.org/0000-0002-9537-8879
Aogi, Kenjiro
Aruga, Tomoyuki
Inoue, Kenichiro
Shimomura, Akihiko
Tokunaga, Eriko
Masuda, Norikazu
Yamauchi, Hideko
Yamashita, Toshinari
Iwata, Hiroji
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (MHLW, 2009 Clinical Cancer Research General-020)
National Cancer Center (2011-A-42)
Article History
Received: 28 December 2019
Accepted: 18 February 2020
First Online: 5 March 2020
Compliance with ethical standards
:
: MA has declared the conflicts related to personal fees from Astra Zeneca K. K., Novartis Pharma K. K., Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Eli Lilly Japan K. K., and Taiho pharmaceutical CO., LTD.; KA received personal fees as honoraria from Chugai Pharmaceutical, Eisai, AstraZeneca, Taiho Pharmaceutical, Novartis Pharma, Daiichi Sankyo, Mochida Pharmaceutical, Ono Pharmaceutical, and Eli Lilly Japan, and his institution received research funds from Chugai Pharmaceutical, Eisai and Sanofi.; TA reports personal fees from CHUGAI PHARMACEUTICAL CO., LTD and Pfizer Japan Inc during the conduct of the study.; KI reports personal fees from Eisai, Chugai, Pfizer, and Eli Lilly, and reports grants from Novartis, Pfizer, Chugai, Daiichi Sankyo, Parexel/Puma Biotechnology, MSD, Bayer, Eli Lilly, and Eisai.; AH reports personal fees from Chugai Pharmaceutical, AstraZeneca, Pfizer, Eli Lilly, Eisai, Daiichi Sankyo, and Novartis, outside the submitted work.; NM has received honoraria from Chugai, AstraZeneca, Pfizer, Eli Lilly, Eisai, and Takeda; funding from Chugai, AstraZeneca, Kyowa Hakko Kirin, MSD, Novartis, Pfizer, Eli Lilly, Eisai, and Daiichi Sankyo.; HY reports personal fees from AstraZeneca K.K., TAIHO PHARMACEUTICAL CO., LTD., Allergan Japan K.K., Pfizer Japan Inc., CHUGAI PHARMACEUTICAL CO., LTD., Novartis Pharma K.K., Shionogi & Co., Ltd., Takeda Pharmaceutical Co., Ltd., NIPPONKAYAKU CO., LTD., TOWA PHARMACEUTICAL CO., LTD., and Elsevier Japan KK during the conduct of the study.; TY reports personal fees as honoraria from Chugai, Eisai, Novartis, Taiho, Nippon Kayaku, AstraZeneca, Kyowa Kirin, Pfizer Japan, and Eli Lilly; and reports grants from Chugai, Taiho, Nippon Kayaku, and Kyowa kirin, outside the submitted work.; HI reports grants and personal fees from Chugai, personal fees from AstraZeneca, personal fees from Daiichi Sankyo, grants and personal fees from Novartis, grants from MSD, grants and personal fees from Lilly, personal fees from Kyowa Hakko Kirin, personal fees from Pfizer, during the conduct of the study; All other authors have declared no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments.
: Informed consent was obtained from all individual participants included in the study.